Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab-Reference-Cited by-同舟云学术

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab

Published:2017-10-24 Issue:61 Volume:8 Page:104149-104159
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Duchnowska Renata¹,Sperinde Jeff²,Czartoryska-Arłukowicz Bogumiła³,Myśliwiec Paulina⁴,Winslow John²,Radecka Barbara⁵,Petropoulos Christos²,Demlova Regina⁶,Orlikowska Marlena⁷,Kowalczyk Anna⁸,Lang Istvan⁹,Ziółkowska Barbara¹⁰,Dębska-Szmich Sylwia¹¹,Merdalska Monika¹²,Grela-Wojewoda Aleksandra¹³,Żawrocki Anton⁸,Biernat Wojciech⁸,Huang Weidong²,Jassem Jacek⁸

Affiliation:

1. Military Institute of Medicine, Warsaw, Poland

2. Holdings, South San Francisco, CA, USA

3. Białystok Oncology Center, Białystok, Poland

4. Oncology Center, Zielona Góra, Poland

5. Opole Oncology Center, Opole, Poland

6. Masaryk Memorial Cancer Institute, Brno, Czech Republic

7. Warmia and Masuria Oncology Center, Olsztyn, Poland

8. Medical University of Gdańsk, Gdańsk, Poland

9. National Institute of Oncology, Budapest, Hungary

10. Regional Hospital, Wrocław, Poland

11. Medical University of Łódź, Łódź, Poland